Comparison of long-term survival of patients with solitary large hepatocellular carcinoma of BCLC stage a after liver resection or transarterial chemoembolization: A propensity score analysis

PLoS ONE

Volumn 9, Issue 12, 2014, Pages

  Zhu, Shao Liang ^a   Ke, Yang ^a,b   Peng, Yu Chong ^a   Ma, Liang ^a   Li, Hang ^a   Li, Le Qun ^a   Zhong, Jian Hong ^a  

^a GUANGXI MEDICAL UNIVERSITY   (China)

^b KUNMING MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA FETOPROTEIN;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALPHA FETOPROTEIN BLOOD LEVEL; ARTICLE; CANCER PATIENT; CANCER STAGING; CHEMOEMBOLIZATION; CONTROLLED STUDY; FEMALE; HUMAN; INTERMETHOD COMPARISON; LIVER CELL CARCINOMA; LIVER RESECTION; LONG TERM SURVIVAL; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OVERALL SURVIVAL; PATIENT SELECTION; PROPENSITY SCORE; RETROSPECTIVE STUDY; SURGICAL MORTALITY; SURVIVAL PREDICTION; SURVIVAL RATE; TUMOR VOLUME; CARCINOMA, HEPATOCELLULAR; COMPARATIVE STUDY; KAPLAN MEIER METHOD; LIVER; LIVER NEOPLASMS; MULTIVARIATE ANALYSIS; PATHOLOGY; PROGNOSIS; TREATMENT OUTCOME;

ADULT; CARCINOMA, HEPATOCELLULAR; CHEMOEMBOLIZATION, THERAPEUTIC; FEMALE; HEPATECTOMY; HUMANS; KAPLAN-MEIER ESTIMATE; LIVER; LIVER NEOPLASMS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROGNOSIS; PROPENSITY SCORE; TREATMENT OUTCOME;

EID: 84919903241     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0115834     Document Type: Article

References (41)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, et al. (2011) Global cancer statistics. CA Cancer J Clin 61: 69-90.
2. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, et al. (2010) Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127: 2893-2917.
3. Sherman M (2010) Epidemiology of hepatocellular carcinoma. Oncology 78 Suppl 1: 7-10.
4. El-Serag HB (2011) Hepatocellular carcinoma. N Engl J Med 365: 1118-1127.
5. Llovet JM, Fuster J, Bruix J (2004) The Barcelona approach: diagnosis, staging, and treatment of hepatocellular carcinoma. Liver Transpl 10: S115-S120.
6. Bruix J, Sherman M (2011) Management of hepatocellular carcinoma: an update. Hepatology 53: 1020-1022.
7. Cillo U, Vitale A, Grigoletto F, Farinati F, Brolese A, et al. (2006) Prospective validation of the Barcelona Clinic Liver Cancer staging system. J Hepatol 44: 723-731.
8. Hsu CY, Huang YH, Chiou YY, Su CW, Lin HC, et al. (2011) Comparison of radiofrequency ablation and transarterial chemoembolization for hepatocellular carcinoma within the Milan criteria: a propensity score analysis. Liver Transpl 17: 556-566.
9. Bargellini I, Sacco R, Bozzi E, Bertini M, Ginanni B, et al. (2012) Transarterial chemoembolization in very early and early-stage hepatocellular carcinoma patients excluded from curative treatment: a prospective cohort study. Eur J Radiol 81: 1173-1178.
10. Hsu K, Chu C, Chan D, Yu J, Shih M, et al. (2012) Superselective transarterial chemoembolization vs hepatic resection for resectable early-stage hepatocellular carcinoma in patients with Child-Pugh class a liver function. Eur J Radiol 81: 466-471.
11. Guo Z, Zhong J, Jiang J, Zhang J, Xiang B, et al. (2014) Comparison of Survival of Patients with BCLC Stage A Hepatocellular Carcinoma After Hepatic Resection or Transarterial Chemoembolization: A Propensity Score-Based Analysis. Ann Surg Oncol: 1-8.
12. Jin Y, Lee J, Choi Y, Chung HJ, Kim YS, et al. (2014) Surgery versus transarterial chemoembolization for solitary large hepatocellular carcinoma of BCLC stage A. J Gastrointest Surg 18: 555-561.
13. Ke Y, Zhong J, Guo Z, Liang Y, Li L, et al. (2014) Comparison liver resection with transarterial chemoembolization for Barcelona Clinic Liver Cancer stage B hepatocellular carcinoma patients on longterm survival after SPSS propensity score matching. Chinese Med J-Peking 94: 747-750.
14. d Agostino RB (1998) Tutorial in biostatistics: propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med 17: 2265-2281.
15. Hsieh CB, Yu CY, Tzao C, Chu HC, Chen TW, et al. (2006) Prediction of the risk of hepatic failure in patients with portal vein invasion hepatoma after hepatic resection. Eur J Surg Oncol 32: 72-76.
16. Zhong J, Xiang B, Gong W, Ke Y, Mo Q, et al. (2013) Comparison of long-term survival of patients with BCLC stage B hepatocellular carcinoma after liver resection or transarterial chemoembolization. PloS one 8: e68193.
17. Chung GE, Lee J, Kim HY, Hwang SY, Kim JS, et al. (2011) Transarterial chemoembolization can be safely performed in patients with hepatocellular carcinoma invading the main portal vein and may improve the overall survival. Radiology 258: 627-634.
18. Vauthey J, Lauwers GY, Esnaola NF, Do K, Belghiti J, et al. (2002) Simplified staging for hepatocellular carcinoma. J Clin Oncol 20: 1527-1536.
19. Pawlik TM, Poon RT, Abdalla EK, Zorzi D, Ikai I, et al. (2005) Critical appraisal of the clinical and pathologic predictors of survival after resection of large hepatocellular carcinoma. Arch Surg 140: 450-458.
20. Kudo M, Okanoue T (2007) Management of hepatocellular carcinoma in Japan: consensus-based clinical practice manual proposed by the Japan Society of Hepatology. Oncology 72: 2-15.
21. Hsu C, Hsia C, Huang Y, Su C, Lin H, et al. (2012) Comparison of surgical resection and transarterial chemoembolization for hepatocellular carcinoma beyond the Milan criteria: a propensity score analysis. Ann Surg Oncol 19: 842-849.
22. Yang L, Fang F, Ou D, Wu W, Zeng Z, et al. (2009) Solitary large hepatocellular carcinoma: a specific subtype of hepatocellular carcinoma with good outcome after hepatic resection. Ann Surg 249: 118-123.
23. Yang L, Xu J, Ou D, Wu W, Zeng Z (2013) Hepatectomy for huge hepatocellular carcinoma: single institute's experience. World J Surg 37: 2189-2196.
24. Zhou L, Rui J, Wang S, Chen S, Qu Q (2011) Prognostic factors of solitary large hepatocellular carcinoma: the importance of differentiation grade. Eur J Surg Oncol 37: 521-525.
25. Choi GH, Han DH, Kim DH, Choi SB, Kang CM, et al. (2009) Outcome after curative resection for a huge (≥10 cm) hepatocellular carcinoma and prognostic significance of gross tumor classification. Am J Surg 198: 693-701.
26. Taniai N, Yoshida H, Tajiri T (2008) Adaptation of hepatectomy for huge hepatocellular carcinoma. J hepatobiliary pancreat surg 15: 410-416.
27. Santambrogio R, Opocher E, Costa M, Barabino M, Zuin M, et al. (2012) Hepatic resection for "BCLC stage A" hepatocellular carcinoma. The prognostic role of alpha-fetoprotein. Ann Surg Oncol 19: 426-434.
28. Yamamoto J, Kosuge T, Saiura A, Sakamoto Y, Shimada K, et al. (2007) Effectiveness of hepatic resection for early-stage hepatocellular carcinoma in cirrhotic patients: subgroup analysis according to Milan criteria. Jpn J Clin Oncol 37: 287-295.
29. Cillo U, Vitale A, Bassanello M, Boccagni P, Brolese A, et al. (2004) Liver transplantation for the treatment of moderately or well-differentiated hepatocellular carcinoma. Ann Surg; 239: 150.
30. Sotiropoulos GC, Drühe N, Sgourakis G, Molmenti EP, Beckebaum S, et al. (2009) Liver transplantation, liver resection, and transarterial chemoembolization for hepatocellular carcinoma in cirrhosis: which is the best oncological approach? Dig Dis Sci 54: 2264-2273.
31. Figueras J, Jaurrieta E, Valls C, Benasco C, Rafecas A, et al. (1997) Survival after liver transplantation in cirrhotic patients with and without hepatocellular carcinoma: a comparative study. Hepatology 25: 1485-1489.
32. Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, et al. (1996) Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. New Engl J Med 334: 693-700.
33. Shrager B, Jibara GA, Tabrizian P, Schwartz ME, Labow DM, et al. (2013) Resection of large hepatocellular carcinoma (≥10 cm): A unique western perspective. J Surg Oncol 107: 111-117.
34. Bertino G, Neri S, Bruno CM, Ardiri AM, Calvagno GS, et al. (2011) Diagnostic and prognostic value of alpha-fetoprotein, des-gamma-carboxy prothrombin and squamous cell carcinoma antigen immunoglobulin M complexes in hepatocellular carcinoma. Minerva Med 102: 363-371.
35. Debruyne EN, Delanghe JR (2008) Diagnosing and monitoring hepatocellular carcinoma with alpha-fetoprotein: new aspects and applications. Clin Chim Acta 395: 19-26.
36. Yang XR, Xu Y, Yu B, Zhou J, Qiu SJ, et al. (2010) High expression levels of putative hepatic stem/ progenitor cell biomarkers related to tumour angiogenesis and poor prognosis of hepatocellular carcinoma. Gut 59: 953-962.
37. Kao W, Chiou Y, Hung H, Su C, Chou Y, et al. (2012) Serum alpha-fetoprotein response can predict prognosis in hepatocellular carcinoma patients undergoing radiofrequency ablation therapy. Clin Radiol 67: 429-436.
38. Kuzuya T, Asahina Y, Tsuchiya K, Tanaka K, Suzuki Y, et al. (2011) Early decrease in α-fetoprotein, but not des-γ-carboxy prothrombin, predicts sorafenib efficacy in patients with advanced hepatocellular carcinoma. Oncology 81: 251-258.
39. Santambrogio R, Opocher E, Costa M, Barabino M, Zuin M, et al. (2012) Hepatic resection for "BCLC stage A" hepatocellular carcinoma. The prognostic role of alpha-fetoprotein. Ann Surg Oncol 19: 426-434.
40. Japan LCSG (1994) Predictive factors for long term prognosis after partial hepatectomy for patients with hepatocellular carcinoma in Japan. Cancer 74: 2772-2780.
41. Investigators COLI (1998) A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients. Hepatology 28: 751-755.